High effectiveness of pandemic influenza A (H1N1) vaccination in healthcare workers from a Portuguese hospital
- First Online:
- 507 Downloads
Vaccination of healthcare workers (HCWs) was made a high priority during the phase six pandemic of the novel influenza A H1N1 (pH1N1) virus. We surveyed adherence to pH1N1 vaccination and the incidence of pH1N1 infection between vaccinated and unvaccinated HCWs.
Employees at the S. João Hospital in Porto, Portugal, were offered pH1N1 vaccinations free of charge. Pandemrix® was the vaccine administered. As part of the pandemic plan, employees with influenza-like symptoms (ILS) were called upon to take an RT-PCR H1N1 test. If the test results were positive, they had to stay off work for at least 7 days. Sociodemographic data, vaccination status, contact with infectious patients, ILS and pH1N1 test results were documented in a standardised manner.
The survey population comprised 5,592 employees. The vaccination rate was 30.8% (n = 1,720) for pH1N1 and 50.4% (n = 2,819) for the 2009/2010 seasonal trivalent inactivated influenza vaccine (TIV). One mild anaphylactic reaction occurred after pH1N1 vaccination. Minor local side effects occurred more often after pH1N1 vaccination than after 2009/2010 seasonal TIV (38.0% vs. 12.3%). Pandemic H1N1 infection was diagnosed in 97 HCWs (1.7%). Compared to employees with no regular patient contact, nurses (2.8%) had the highest risk of pH1N1 infection (adjusted OR 3.8; 95% CI 1.2–6.8). Vaccination reduced the pH1N1 infection risk (OR 0.12; 95% CI 0.05–0.29). Vaccine effectiveness was 90.4% (95% CI 73.5–97.3%).
Vaccination reduced the pH1N1 infection risk considerably. The pandemic plan to contain the pH1N1 infection was successful. Nurses had the highest risk of pH1N1 infection and are therefore a target group for vaccination measures.
KeywordsPandemic influenza A H1N1 Healthcare workers Vaccination
Pandemic influenza A H1N1
Trivalent inactivated influenza vaccine
Real-time reverse transcriptase–polymerase chain reaction
In the middle of April 2009, cases of infection with a new influenza virus were detected in Mexico and southern California (MMWR 2009). This virus was later identified as an H1N1 influenza virus, with six genes derived from triple-reassortant North American swine virus lineages and two genes (encoding neuraminidase and matrix proteins) derived from Eurasian swine virus lineages (Garten et al. 2009). It rapidly spread to many countries around the world, prompting the World Health Organization (WHO) to declare a phase six global influenza pandemic on 11 June 2009 (WHO 2009a). At that time, 74 countries had reported over 27,000 cases of pandemic influenza A H1N1 (pH1N1) and 141 deaths (WHO 2009b). Three months later, the virus had spread to over 170 countries and was estimated to have caused 3,486 deaths (WHO 2009c).
The development of an effective vaccine against the new strain of the virus and the subsequent implementation of a large-scale immunisation campaign was considered one of the most effective ways to control the pandemic. The immunisation of healthcare workers (HCWs) was given high priority in order to protect the healthcare infrastructure (WHO 2009d).
In Portugal, a national vaccination plan against the pH1N1 virus was implemented, using the vaccine Pandemrix®, containing 3.75 μg of haemagglutinin (General Directorate of Health 2009). It was available from the second half of October 2009. According to national guidelines, the vaccine was to be given to priority groups including HCWs and emergency medical services personnel. The aim of our study was to analyse the incidence of pH1N1 influenza and the effectiveness of pH1N1 vaccination in HCWs at a Portuguese tertiary referral teaching hospital.
The pH1N1 vaccination was offered to all HCWs working at S. João Hospital in Porto, Portugal, during the influenza season 2009/2010. Vaccination started on 26 October 2009. No predetermined end date for the vaccination campaign was given. On 10 January 2010, the last HCW was vaccinated. Participants were asked to remain under observation for 60 min after vaccination so that any side effects could be identified. The observation period was limited to 1 h because if severe side effects, i.e. anaphylactic reaction, occur they will be apparent within the first hour after vaccination. Furthermore, HCWs were asked to actively report any side effects of the vaccination to the vaccination desk in an informal manner. In addition, HCWs were either asked directly during their next visit to the OSH-department or contacted by phone within 3 months of their pH1N1 vaccination and asked whether any side effects occurred. For this interview, a semi-standardised survey was used containing a list of potential side effects such as soreness, redness or swelling at injection site, muscle aches, or fever.
Seasonal vaccination 2009/2010 commenced on 14 September 2009 using the trivalent inactivated influenza vaccine (TIV) CHIROFLU® from Novartis Lab. In those participants with a previous seasonal vaccination, side effects of the vaccination were assessed at the time of the pH1N1 vaccination. Both pH1N1 and seasonal vaccination were given free of charge to the HCWs and information regarding the vaccinations was disseminated in a similar fashion within the hospital.
According to the contingency plan for pH1N1 control, HCWs with influenza-like symptoms (ILS) were attended to by a specialised physician at the pH1N1 task force unit created in the Emergency Department. The task force examined HCWs with ILS and offered antiviral treatment. This treatment was only available in the hospital. A nasopharyngeal or oropharyngeal tissue swab was taken from each HCW with ILS for the detection of the pH1N1 virus, using the real-time reverse transcriptase–polymerase chain reaction (RT-PCR) method.
All HCWs were monitored by the Occupational Health Division and requested to stay at home until the test results were known. The HCWs were allowed to return to their usual workplace if the result of the RT-PCR was negative and the symptoms had improved. However, if the RT-PCR was positive, the HCWs had to stay at home for a period of at least 7 days. This sick leave did not result in any loss of income or benefits regardless of the RT-PCR result. The analysis is restricted to ILS or pH1N1 infections that occurred after pH1N1 vaccination was available. Before 26 October, only eleven cases of ILS and two cases of pH1N1 infection were registered. Before the swab was taken, symptoms were recorded and HCWs were asked whether they had had contact with patients or other persons with ILS.
The contingency plan for pH1N1 control not only recommended vaccination, antiviral treatment and social distancing but also emphasised disinfection, hand-washing and use of masks in order to prevent transmission. However, these latter aspects were not part of this analysis.
Data analysis was performed with SPSS, version 13. Adjusted odds ratio (OR) and 95% confidence interval (CI) for putative risk factors for ILS or pH1N1 infection were calculated. Pearson’s Chi-square test was employed for categorical data using α < 0.05 as the significance level. The number of prevented cases of pH1N1 influenza was calculated by subtracting the observed cases in vaccinated HCWs from the expected cases had the HCWs not been vaccinated. Vaccine effectiveness (VE) was estimated using the following formula: VE = (PPV−PCV)/(PPV(1−PCV)) × 100%, where PPV is the proportion vaccinated in the cohort and PCV the proportion of vaccinated cases (Farrington 1993). For this calculation, an HCW was considered vaccinated when the onset of symptoms started later than 1 week after the vaccination. The ethical integrity of the study was confirmed by the pH1N1 task force (General Directorate of Health 2009) and HCWs gave their informed consent to an anonymous analysis of their data.
Description of the study population (n = 5,592)
Administration or others
Seasonal 09/10 TIV
Seasonal 08/09 TIV
TIV in 2008/2009
TIV in 2009/2010
TIV in both seasons
Influenza-like symptoms (ILS)
Confirmed pH1N1 infection
Seasonal TIV and 2009 pH1N1 vaccination rates by profession
Administration or others
Side effects of seasonal vaccination 09/10 in those 1,144 HCWs who obtained pH1N1 vaccination and side effects of pH1N1 vaccination
2009/2010 seasonal TIV
No side effects
Temperature > 38°C
Lymph node swelling
Mild local reaction
Strong local reaction
Between 26 October 2009 and 2 March 2010, 245 HCWs with ILS (4.4%) were referred to the pH1N1 task force in the Emergency Department (Table 1). Of these, pH1N1 virus infection was confirmed in 97 cases (39.6%). Indeterminate results were observed in two out of 245 examinations (0.8%). After performing a second test, one case remained indeterminate.
Logistic regression for putative risk factors of influenza-like symptoms (ILS)
Seasonal TIV 09/10
Administration or others
Logistic regression for putative risk factors for pH1N1 infection
Seasonal TIV 09/10
Administration or others
Sixty-two (64%) of the pH1N1 infected HCWs had had known contact with a pH1N1 infected individual and another 17 HCWs (17.5%) had had contact with symptomatic individuals. Fifty out of 79 potential sources of infection (63%) were patients in the hospital. The most frequent symptoms associated with pH1N1 infection were muscle or joint pain (85%), coughing (78%), fever (77%), headache (61%) and sore throat (40%). The disease was benign in its evolution in all cases.
To our knowledge, this is the first study to analyse the incidence of pH1N1 infection and vaccine effectiveness in HCWs in the 2009/2010 season. According to our data, nurses were the most affected group. Most of the known infectious contacts were with patients. The vaccination rate was 30.8, and 94% of the pH1N1 infections were observed in the unvaccinated HCWs. Vaccination reduced the attack rate of pH1N1 from 2.4 to 0.3%. Vaccination may have prevented 35 pH1N1 infections in this particular cohort and pandemic season. Calculated vaccine effectiveness was 90.4% and therefore high.
The pandemic plan at S. João Hospital ensured that no HCWs who took sick leave due to ILS suffered any loss of income or benefits. This was granted to all HCWs with ILS regardless of whether it was caused by pH1N1 infection or not. Furthermore, antiviral treatment was only offered to those who reported to the Emergency Department. These two circumstances increased the likelihood of reporting ILS. Therefore, this could well have neutralised any potential reluctance to report ILS to the pandemic task force. However, asymptomatic infections could not be detected by testing HCWs with ILS only and infections with mild symptoms are likely to have been underreported. This limitation renders it likely that the incidence of pH1N1 infection was underestimated in our cohort. However, underreporting was most likely non-differential and therefore did not influence the estimate of vaccine effectiveness. In a previous German study, vaccine effectiveness was estimated to be 96.8% in the general population (Wichmann et al. 2010). Therefore, the vaccine effectiveness we found in HCWs (90.4%) was slightly lower. For the United Kingdom, a lower vaccine effectiveness of 71% was reported (Hardelid et al. 2011). Vaccine effectiveness increased to 72% if vaccination was assumed to be effective 2 weeks after injection instead of one, as we assumed. In a European multicentre study, vaccine effectiveness was 78.4% in persons <65 years (Valenciano et al. 2011). Therefore, our observation is well within the range of vaccine effectiveness found in other populations.
The vaccination rate against the pH1N1 virus (30.8%) was significantly lower than for the seasonal TIV in the same year (50.4%). Similar ratios were also described by other authors, with pH1N1 vaccination levels varying, depending on country and institution, between 15 and 37% (Wicker et al. 2010; Sullivan et al. 2010). The main cause of pandemic vaccine refusal was concern about its safety and the belief that it was not needed (Rachiotis et al. 2010; SteelFisher et al. 2010; Ofri 2009). Our data suggest that the pH1N1 vaccination was safe and effective. Side effects were more frequent after pH1N1 vaccination than after seasonal TIV. However, they were mostly minor local reactions. As a limitation of the study, it should be noted that underreporting of side effects of seasonal TIV is possible if side effects of seasonal TIV discouraged HCWs from accepting pH1N1 vaccination. Underreporting of side effects caused by the pH1N1 vaccination is not likely because in addition to active reporting of side effects to the vaccination desk a survey on side effects was performed with all HCWs who received the vaccination. The frequency of side effects we observed was similar to that described in an Italian HCWs study, which reported pain at the injection site (43.4%) as the most frequent adverse reaction (Amodio et al. 2011). As increased knowledge and awareness could well have an improved impact on adherence to vaccination schemata, our data might help to convince HCWs to take part in vaccination campaigns for the coming influenza seasons (Hofmann et al. 2006).
Seasonal influenza vaccination was not effective against pH1N1 infection. This corroborates the findings of Jefferies et al. (2011) from New Zealand. The authors conclude that 2009 seasonal influenza vaccination had no protective effect against pH1N1 infection amongst HCWs.
The major limitation of our study is that only participants with ILS were tested for pH1N1 infection. There might have been underreporting of ILS, and a certain number of pH1N1 infections might have been asymptomatic and therefore remained unnoticed. However, surveys on the incidence of pH1N1 infections describe infection rates very similar to our findings in HCWs who were not vaccinated (Reed et al. 2009, 2011; Santos et al. 2010; Brammer et al. 2011). This corroborates the infection rates we found and renders serious underreporting unlikely. Furthermore, the sensitivity and specificity of the RT-PCR for pH1N1 are suitable for diagnostic use but they are not perfect (Ellis et al. 2009). Tests for antibodies after the infection or ILS were not performed in order to confirm the pH1N1 infection. This might have resulted in false positive or false negative results. However, this should have led to non-differential misclassification and dilution of the preventive effect of pH1N1 vaccination. Therefore, the vaccine effectiveness observed in our study is unlikely to be overestimated. Side effects of the pH1N1 vaccination were directly observed during the first hour after vaccination. It should be noted that information on other side effects was based on informal reports to the vaccination desk and a semi-standardised survey either in person or over the phone. Therefore, underestimation of the incidence of side effects after pH1N1 vaccination is possible but not likely to introduce a significant bias.
Vaccine effectiveness seemed to be high in HCWs during the influenza A H1N1 season 2009/2010. The pandemic plan to contain pandemic influenza A H1N1, with its various methods, was successful. The use of vaccines significantly reduced the expected number of illnesses. Nurses had the highest risk of pH1N1 infection and are therefore a target group for vaccination measures.
We would like to thank the HCWs who participated in this study. No funds were received for this study.
Conflict of interest
The authors declare that they have no conflict of interest.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
- Brammer L, Blanton L, Epperson S et al (2011) Surveillance for influenza during the 2009 influenza A (H1N1) pandemic-United States, April 2009–March 2010. Clin Infect Dis 52(Suppl 1):S27–S35Google Scholar
- Ellis J, Iturriza M, Allen R et al (2009) Evaluation of four real-time PCR assays for detection of influenza A (H1N1) virus. Euro Surveill 14(22)Google Scholar
- General Directorate of Health (2009) Vaccination campaign against the pandemic influenza (H1N1) 2009 infection. Information bulletin no. 17, 14 October 2009 (Direcção-Geral da Saúde (2009) Campanha de vacinação contra a infecção pelo vírus da gripe pandémica (H1N1). Circular Normativa no 17, 14 October 2009)Google Scholar
- Hardelid P, Fleming DM, McMenamin J et al (2011) Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A (H1N1) 2009 infection in England and Scotland 2009–2010. Euro Surveill 16(2):pii19763Google Scholar
- Jefferies S, Earl D, Berry N et al (2011) Effectiveness of the 2009 seasonal influenza vaccine against pandemic influenza A (H1N1) 2009 in healthcare workers in New Zealand. Euro Surveill 16(2)Google Scholar
- MMWR (2009) Swine influenza A (H1N1) infection in two children—Southern California, March–April 2009. MMWR Morb Mortal Wkly Rep 58:400–402Google Scholar
- Rachiotis G, Mouchtouri VA, Kremastinou J, Gourgoulianis K, Hadjichristodoulou C (2010) Low acceptance of vaccination against the 2009 pandemic influenza A (H1N1) among healthcare workers in Greece. Euro Surveill 15(6):pii=19486Google Scholar
- Reed C, Angulo FJ, Biggerstaff M, Swerdlow DL, Finelli L (2011) Influenza-like illness in the community during the emergence of 2009 pandemic influenza a (H1N1)-survey of 10 states, April 2009. Clin Infect Dis 52(Suppl 1):S90–S93Google Scholar
- Santos CD, Bristow RB, Vorenkamp JV (2010) Which health care workers were most affected during the spring 2009 H1N1 pandemic? Disaster Med Public Health Prep 4(1):47–54Google Scholar
- Wichmann O, Stocker P, Poggensee G, Altmann D, Walter D, Hellenbrand W, Krause G, Eckmanns T (2010) Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009–2010. Euro Surveill 15(18)Google Scholar
- World Health Organization (WHO) (2009a) New influenza A/H1N1 virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 84:249–257Google Scholar
- World Health Organization (WHO) (2009b) Information for the media—influenza A (H1N1): WHO announces pandemic alert phase 6, of moderate severity. WHO press, release:06Google Scholar
- World Health Organization (WHO) (2009c) Pandemic (H1N1) 2009—update 66. WHO 09:18Google Scholar
- World Health Organization (WHO) (2009d) WHO recommendations on pandemic (H1N1) 2009 vaccines. Pandemic (H1N1) 2009 briefing note 2. WHO 07:13Google Scholar